<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039775</url>
  </required_header>
  <id_info>
    <org_study_id>Hend3</org_study_id>
    <nct_id>NCT05039775</nct_id>
  </id_info>
  <brief_title>Clitoral Therapy Device in Alleviating Sexual Dysfunction After Genital Mutilation.</brief_title>
  <official_title>Clitoral Therapy Device in Alleviating Sexual Dysfunction After Genital Mutilation of Females in Egypt.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Badr University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Badr University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study to determine the effect of clitoral therapy device EROS device/ on&#xD;
      sexual dysfunction after genital mutilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Little attention has been given to women who exposed to genital mutilation surgery in early&#xD;
      age in the middle east. Most of them suffer from sexual dysfunction of sexual arousal and&#xD;
      orgasm when they get in an intimate relation with their husbands after marriage. Clitoral&#xD;
      therapy device may improve sexual arousal and alleviate sexual dysfunction symptoms to a&#xD;
      great extent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Female Sexual Function Index (FSFI).</measure>
    <time_frame>Change from baseline sexual function at 3 months.</time_frame>
    <description>Female sexual dysfunction has traditionally included disorders of desire. libido, arousal, pain/discomfort, and inhibited orgasm.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>Sexual Arousal Disorder</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal and will use EROS-CTD Clitoral Therapy Device and will be closely followed for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Forty married women, their ages will range from 20 to 45 years and all are suffering sexual dysfunction of sexual arousal will not receive any treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EROS device</intervention_name>
    <description>Eros is a small, hand-held device fitted with a removable, replaceable small plastic cup used as a natural way to initiate female sexual response. It was originally cleared by the FDA in April 2000 for the treatment of Female Sexual Arousal Disorder (FSAD), which includes problems with sexual arousal and orgasm.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Clitoral therapy device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All are suffering sexual dysfunction of sexual arousal and all referred from the&#xD;
             family planning and reproductive health department, National research Center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease, severe bowel or bladder sequelae, and significant comorbidities.&#xD;
             Women with a history of sexual trauma or abuse, or undergoing current antidepressant&#xD;
             therapy were excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study is targeting females who subjected to genital mutilation affecting their sexual life after marriage.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amr Abbassy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HEND SAKR, PhD</last_name>
    <phone>+201010151300</phone>
    <email>hend.reda@buc.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariam El-Ebrashy, PhD</last_name>
    <phone>+201001716570</phone>
    <email>dr_mariam_elebrashy@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Badr University in Cairo</name>
      <address>
        <city>New Cairo</city>
        <state>Badr City</state>
        <zip>11829</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hend Sakr, PhD</last_name>
      <phone>+201010151300</phone>
      <email>hend.reda@buc.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Amr Abbassy, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Badr University</investigator_affiliation>
    <investigator_full_name>Hend Reda Sakr</investigator_full_name>
    <investigator_title>Lecturer of Physical Therapy for Woman's Health</investigator_title>
  </responsible_party>
  <keyword>Sexual arousal disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

